• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Bridge­Bio CEO Neil Ku­mar en­gi­neers a deal to reel back Ei­dos shares. Or is he re­al­ly hunt­ing a buy­out?

6 years ago
Deals

Hu­mana takes aim at Mallinck­rodt's 'ill-got­ten' Ac­thar gains in law­suit

6 years ago
Pharma
FDA+

FDA so­lic­its in­dus­try in­put for OND pol­i­cy pri­or­i­ties

6 years ago
FDA+

A top an­a­lyst spot­lights a wave of biotech star­tups look­ing to cat­a­pult on­to Nas­daq — or get bought out

6 years ago
Financing

Pref­er­en­tial tax poli­cies com­ing for bio­phar­mas set­ting up shop in Shang­hai's newest free trade zone

6 years ago
China

Am­gen at­tor­neys win a megablock­buster patent case, deal­ing No­var­tis a se­vere set­back on biosim­i­lars play

6 years ago
Pharma

US sen­a­tors ac­cuse No­var­tis ex­ecs of greed for hid­ing ma­nip­u­lat­ed Zol­gens­ma da­ta — and the next step could af­fect ...

6 years ago
Pharma
FDA+

Retrophin paid Mar­tin Shkre­li 'undis­closed sum' to set­tle years­long le­gal dis­putes

6 years ago
People

FDA re­jects Kala's dry eye drug; Trou­bled In­sys finds a buy­er (of some as­sets) in Hik­ma

6 years ago
News Briefing

Top Scripps sci­en­tist and biotech co-founder makes an abrupt — and un­ex­plained — ex­it

6 years ago
R&D

Ap­ple de­vices, in tan­dem with dig­i­tal apps, could de­tect ear­ly signs of Alzheimer's, de­men­tia: study

6 years ago
R&D

Melin­ta chief John John­son jumps ship — with the chair­man — from an­oth­er trou­bled an­tibi­otics play

6 years ago
People

Fab­ry dis­ease: FDA drafts drug de­vel­op­ment guid­ance

6 years ago
FDA+

Amy Bur­roughs to lead Cleave Ther­a­peu­tics; Cyn­thia Collins clinch­es Ed­i­tas CEO job amid his­toric CRISPR move

6 years ago
Peer Review

As­traZeneca's flag­ship Tagris­so helps lung can­cer pa­tients live longer in piv­otal study

6 years ago
R&D
Pharma

Mys­tery solved? Nek­tar chief says 'soft­en­ing' in pa­tient re­spons­es to be­m­peg was a CMC is­sue — spurring a rout

6 years ago
R&D

The FDA de­cides to hold an ex­pert pan­el re­view of Vas­cepa af­ter all — and Amarin shares tank on un­ex­pect­ed de­lay

6 years ago
R&D
FDA+

Sarep­ta shares slammed on re­port gene ther­a­py Duchenne MD pa­tient was hos­pi­tal­ized, but the com­pa­ny says it is ...

6 years ago
R&D
Pharma

Boris John­son pledges £250M to spur AI adop­tion in NHS; SQZ scoops CFO Teri Lox­am from Mer­ck

6 years ago
News Briefing

New ex­ec team, new mon­ey and a big syn­di­cate — ORIC heads to PhII

6 years ago
R&D

Alexan­dria seals $143M deal in Seat­tle's 'heart of the heart,' grab­bing cov­et­ed land to build its biotech clus­ter

6 years ago
Startups

More re­search is need­ed to jus­ti­fy use of 'med­i­c­i­nal' cannabis: UK agen­cies

6 years ago
FDA+

The FDA’s very pub­lic slap of No­var­tis’ red face is a warn­ing to the en­tire in­dus­try — don’t down­play it

6 years ago
Bioregnum
Opinion

FDA Ad­Com backs Gilead­'s move to ex­pand De­scovy la­bel — but stops short of en­dors­ing broad PrEP use

6 years ago
R&D
Pharma
First page Previous page 909910911912913914915 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.